Abstract:Background & Aims: Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as NAFLD, is a leading cause of chronic liver disease worldwide. Current diagnostic methods, including liver biopsies, are invasive and have significant limitations, emphasizing the need for non-invasive alternatives. This study aimed to evaluate extracellular vesicles (EV) as biomarkers for diagnosing and staging steatosis in MASLD patients, utilizing machine learning (ML) and explainable artificial intelligence (XAI). Methods: This prospective, single-center cohort study was conducted at the GI-Liver Unit, Hippocration General Hospital, Athens. It included 76 MASLD patients with ultrasound-confirmed steatosis and at least one cardiometabolic risk factor. Patients underwent transient elastography for steatosis and fibrosis staging and blood sampling for EV analysis using nanoparticle tracking. Twenty machine learning models were developed. Six to distinguish non-steatosis (S0) from steatosis (S1-S3), and fourteen to identify severe steatosis (S3). Models incorporated EV measurements (size and concentration), anthropomorphic and clinical features, with performance evaluated using AUROC and SHAP-based interpretability methods. Results: The CB-C1a model achieved, on average on 10 random splits of 5-fold cross validation (5CV) of the train set, an AUROC of 0.71/0.86 (train/test) for distinguishing S0 from S1-S3 steatosis stages, relying on EV alone. The CB-C2h-21 model identified severe steatosis (S3), on average on 10 random splits of 3-fold cross validation (3CV) of the train set, with an AUROC of 0.81/1.00 (train/test), demonstrating superior performance when combining EV with anthropomorphic and clinical features such as diabetes and advanced fibrosis. Key EV features, including mean size and concentration, were identified as important predictors. SHAP analysis highlighted complex non-linear relationships between features and steatosis staging. Conclusions: EV are promising non-invasive biomarkers for diagnosing and staging MASLD. The integration of ML-enhanced EV analysis with clinical features offers a scalable, patient-friendly alternative to invasive liver biopsies, advancing precision in MASLD management. Further research should refine these methods for broader clinical application. Keywords: Metabolic dysfunction-associated steatotic liver disease (MASLD), extracellular vesicles (EVs), non-invasive biomarkers, machine learning (ML), explainable artificial intelligence (XAI), steatosis staging, transient elastography, chronic liver disease, cardiometabolic risk factors, SHAP analysis, diagnostic precision, advanced fibrosis, severe steatosis (S3), liver biopsy alternatives, hepatology diagnostics.

Novel eicosanoid signature in plasma provides diagnostic for metabolic dysfunction-associated steatotic liver disease

A prognostic molecular signature of hepatic steatosis is spatially heterogeneous and dynamic in human liver

Multipanel Approach including miRNAs, Inflammatory Markers, and Depressive Symptoms for Metabolic Dysfunction-Associated Steatotic Liver Disease Diagnosis during 2-Year Nutritional Intervention

Plasma ALS and Gal-3BP differentiate early from advanced liver fibrosis in MASLD patients

Deep Proteome Profiling of Metabolic Dysfunction-Associated Steatotic Liver Disease

Unmasking the enigma of lipid metabolism in metabolic dysfunction-associated steatotic liver disease: from mechanism to the clinic

Development of a Plasma Screening Panel for Pediatric Nonalcoholic Fatty Liver Disease Using Metabolomics

Validation of a screening panel for pediatric metabolic dysfunction–associated steatotic liver disease using metabolomics

Increased Odds of Metabolic Dysfunction-Associated Steatotic Liver Disease Are Linked to Reduced n-6, but Not n-3 Polyunsaturated Fatty Acids in Plasma

Evaluation of the Diagnostic Utility of Selected Serum Adipokines and Cytokines in Subjects with MASLD—A Pilot Study

Non-invasive Scores and Serum Biomarkers for Fatty Liver in the Era of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Comprehensive Review From NAFLD to MAFLD and MASLD

A Precision Medicine Guided Approach to the Utilization of Biomarkers in MASLD

Diagnostic performance of sixteen biomarkers for MASLD: A study in a Mexican cohort

Omics-based biomarkers as useful tools in metabolic dysfunction-associated steatotic liver disease clinical practice: How far are we?

Inflammatory Markers As Diagnostic And Precision Nutrition Tools For Metabolic Dysfunction-Associated Steatotic Liver Disease: Results From The Fatty Liver In Obesity Trial

Extracellular Vesicles as Biomarkers for Steatosis Stages in MASLD Patients: an Algorithmic Approach Using Explainable Artificial Intelligence

Non-invasive testing in metabolic dysfunction-associated steatotic liver disease

Biomarkers of NAFLD Progression: a Lipidomics Approach to an Epidemic

Evaluating cardiovascular risk in metabolic steatosis with precision medicine non-invasive approaches: insights from a cohort study

Circulating microRNA panels in subjects with metabolic dysfunction-associated steatotic liver disease after following a 2-year dietary intervention

Relationship Between Metabolic Dysfunction-Associated Steatotic Liver Disease and Lipoprotein (a) and Other Biomarkers